<DOC>
	<DOCNO>NCT02299648</DOCNO>
	<brief_summary>This protocol screen protocol . No drug intervention study include protocol . However , base molecular profiling , patient may eligible targeted agent . However , molecular profile n't guarantee enrollment onto clinical trial . Currently , available drug AKT inhibitor , MEK inhibitor , Wee1 inhibitor , MET inhibitor . ATR inhibitor agent may available context clinical trial depend availability .</brief_summary>
	<brief_title>The Screening Protocol The VIKTORY Trial</brief_title>
	<detailed_description>To screen metastatic GC patient fail progressed first-line chemotherapy . Patients undergo biopsy tumor analyze use cancer panel/nanostring CNV immunohistochemistry . This protocol screen protocol inform consent form obtain accord biomarker profile protocol eligible . Informed consent obtain patient gastric adenocarcinoma analysis fresh tissue archival FFPE Samsung Medical Center perform . Patients prior complete first-line chemotherapy ( fluoropyramidine/platinum-based ) eligible screening . After analysis , pathologic molecular biologic verification process validity result proceed . The biopsy perform first-line treatment molecular analysis . The patient screen protocol undergo baseline biopsy first-line therapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Pathologically confirm Metastatic recurrent esophageal , gastroesophageal gastric adenocarcinoma Progressed and/or complete one platinum/fluoropyrimidinebased cytotoxic chemotherapy regimen ( adjuvant treatment consider one palliative regimen ) : patient prior complete firstline chemotherapy eligible screening . Tissue specimen : surgical specimen , endoscopic biopsy , colono/sigmoidoscopic biopsy , liver biopsy , lymph node biopsy , malignant cell isolated ascites/pleural effusion/pericardial effusion/other malignancy relate body fluid sufficient number malignant cell DNA/RNA extraction allow . Age ≥ 20 year 5 ) ECOG performance status 01 6 ) Written inform consent Life expectancy ≥ 3 month Patients available archival tissue molecular analysis patient agree biopsy molecular analysis ( however , fresh frozen tissue consider first ) Prior history taxane treatment palliative chemotherapy Uncontrolled systemic illness infection Pregnant nursing woman HER2 3+ GC HER2 2+ GC HER2 amplification FISH SISH</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>